This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2017
ASCO GU 2017
Press Releases
Prostate Cancer
Kidney Cancer
Penile, Urethral & Testicular Cancer
Bladder Cancer
ASCO GU 2017 Kidney Cancer
Viewing 1-19 of 19 articles
ASCO 2017: Identifying and Targeting Genetic Drivers in Rare Genitourinary Cancer Types
ASCO GU 2017: Best of Journals: Renal Cell Carcinoma – Medical Oncology - Session Highlights
ASCO GU 2017: Optimal Selection of Front-Line Therapies for Metastatic Renal Cell Carcinoma - Session Highlights
ASCO GU 2017: A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). - Session Highlights
ASCO GU 2017: Evolving Treatment Using Tyrosine Kinase Inhibitors and Immunotherapy in Metastatic Renal Cell Carcinoma - Session Highlights
ASCO GU 2017: Adjuvant Therapy of Renal Cell Carcinoma: Current Controversies - Session Highlights
ASCO GU 2017: Imaging as Biomarker of Response in Advanced Renal Cell Carcinoma - Session Highlights
ASCO GU 2017: Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC) - Session Highlights
ASCO GU 2017: Evolution of circulating tumor DNA profile from 1st line to 2nd line therapy in metastatic renal cell carcinoma. - Session Highlights
ASCO GU 2017: Cryoablation of cT1 renal masses in the “healthy” patient: Early outcomes from Mayo Clinic. - Session Highlights
ASCO GU 2017: Comparative effectiveness of tumor response assessment methods: Standard-of-care versus computer-assisted response evaluation. - Session Highlights
ASCO GU 2017: Phase II Study Supports Potential For Genentech’s TECENTRIQ® (ATEZOLIZUMAB) PLUS AVASTIN® (BEVACIZUMAB) For People With Locally Advanced or Metastatic Renal Cell Carcinoma - Session Highlights
ASCO GU 2017: Intermediate-term outcomes from the DISSRM registry: A prospective analysis of active surveillance in patients with small renal masses. - Session Highlights
ASCO GU 2017: Use of Ablation in Small Renal Tumors - Session Highlights
ASCO GU 2017: Novel Imaging Modality: Radiographic Biopsy - Session Highlights
ASCO GU 2017: Contemporary Role of Percutaneous Biopsy for the Small Renal Mass - Session Highlights
ASCO GU 2017: The Evolving Role of Active Surveillance in Small Renal Tumors - Session Highlights
ASCO GU 2017: Best of Journals: Renal Cell Carcinoma – Urologic Oncology - Session Highlights
ASCO GU 2017: Best of journals: Renal Cell Carcinoma - Radiologist - Session Highlights
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free